PR NewsWire | Sep 17 2024
- Zoetis is introducing Vetscan® OptiCell™ to Australia as it continues to transform diagnostics with its suite of integrated products and services
- The new haematology analyser offers innovative AI-powered technology for CBC analysis, providing lab quality accuracy1 at the point of care
- The analyser represents significant time, cost and space savings for veterinarians with minimal maintenance requirements
SYDNEY, Sept. 17, 2024 /PRNewswire/ — Zoetis Inc., the world’s leading animal health company, is set to unveil its new haematology analyser Vetscan® OptiCell™, a cartridge-based, AI-powered diagnostic tool for more advanced Complete Blood Count (CBC) analysis. The analyser – to be introduced to Australia later this year – represents a significant leap in technology and offers meaningful time, cost, and space savings for veterinary teams, to enable better patient outcomes and a more efficient clinic workflow.
Vetscan OptiCell reaffirms Zoetis’ longstanding commitment to advancing veterinary medicine through meaningful innovation. The latest addition to Zoetis’ suite of diagnostic products and services offers a more advanced approach to haematology by utilising cell-focusing and AI-powered classification technology for CBC analysis, delivering lab quality accuracy1 at the point of care.
Abhay Nayak, President of Global Diagnostics at Zoetis said: "This latest innovation further strengthens our haematology story, particularly when partnered with Vetscan Imagyst® AI Blood Smear – reinforcing the existing capabilities of Zoetis’ Virtual Laboratory portfolio to provide a comprehensive and connected platform."
Dr. Richard Goldstein, DVM, DACVIM, DECVIM-CA, Global Chief Medical Officer and Head of Medical Affairs at Zoetis said: "Vetscan OptiCell delivers high-quality results, enables improved efficiency, and provides a compact footprint. For the first time, we are able to use advanced AI image recognition technology to characterize the blood cells instead of relying on their size or other physical parameters. This is an important step forward for our haematology story, demonstrating Zoetis’ devotion to the well-being of animals and those that care for them."
The innovative cartridge-based solution joins Vetscan® HM5 as the second Zoetis Diagnostics haematology analyser available to customers, further expanding the in-clinic capability to count and characterise blood cells. Combined with the pioneering AI-powered Vetscan Imagyst analyser, the state-of-the-art suite of products and services characterises the future of veterinary diagnostics.
The first international public viewing of the new analyser will be at the London Vet Show, stand N50, ExCel London, UK, 14-15 November 2024. Pre-orders will be available for customers in Australia in late 2024.
Supported by the Virtual Laboratory’s integrated network of board-certified specialists, this portfolio provides world-leading pathology expertise at the fingertips of veterinarians and delivers deeper insights to elevate care.
To schedule an interview, please contact Garnett Keeler PR.
For more information about OptiCell, visit http://www.zoetisdiagnostics.com.au/opticell
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; disruptions in our global supply chain; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development, expected timing of product launches; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; tax rate and tax regimes and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections thereof captioned "Forward-Looking Statements and Factors That May Affect Future Results" and "Item 1A. Risk Factors," in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
References
1. Data on file, Study No. DHXMZ-US-24-235, Zoetis Inc.
Zoetis Australia Pty Ltd. ABN 94 156 476 425. Level 6, 5 Rider Boulevard, Rhodes, NSW 2138. © 2024 Zoetis Inc. All rights reserved. August 2024. MM-35527
Photo – https://mma.prnewswire.com/media/2506464/Zoetis_Vetscan_OptiCell.jpg
